Mylan Pharmaceuticals has launched a fixed dose combination drug in India for treatment-experienced adults and adolescents weighing more than 40 kg with HIV-1.
The product, DURART R 450, comprises Darunavir/Ritonavir 400/50mg. Alternative treatments require patients to take two drugs separately. This is the first FDC drug available to patients in India, the company said in a release on Thursday.
President (India and Emerging Markets) Rakesh Bamzai said patients with HIV-1 will now have access to the fixed-dose combination therapy which may improve the overall patient treatment outcomes. Darunavir and Ritonavir are HIV protease inhibitors and can be used in combination for patients failing first and second-line regimens during the management of HIV-1 infection. Darunavir is currently available in India in 600 mg and 800 mg dose forms and Ritonavir is available in the 100 mg and 50 mg dose forms.
The company’s ARV portfolio includes 14 APIs and 50 finished dosage forms in first-line, second-line and paediatric formulations, the release said.
